The Global Anti-epileptic Drugs for Pediatrics Market by drug type (1st generation, 2nd generation, and 3rdgeneration) and region (North America, Latin America, Europe, Asia-Pacific, the Middle East and Africa) was valued at US$ 671.9 million in 2016 and is projected to exhibit a CAGR of 7.9% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Growing incidence of epilepsy and associated co-morbidities are expected to be the major factors driving growth of the global anti-epileptic drugs for pediatrics market over the foreseeable future.
Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/823
Manufacturers are focusing on upgrading the available treatment options as well as developing new solutions for chronic as well as refractory epilepsies. Improving the therapeutic efficacy and effectiveness while lowering the side effects and interactions for better effects in adjunctive therapies is the epicenter of research and development for new treatment options in terms of drugs. For instance, Pfizer, Inc. entered into partnership with Epilepsy Foundation to find solutions for generic forms of epilepsy and associated neurological disorders also, in 2016, Pfizer, Inc.’s Lyrica (pregabalin) cleared phase-3 clinical trials for prescription to pediatric patients. Furthermore, UCB Pharma Limited received the U.S. FDA-approval for Briviact, for the treatment of patients with partial onset seizures.
Manufacturers are also working on existing issues associated with epilepsy treatment for children, through research and development activities of pipeline products and by exploring the effectiveness of generic drugs as compared to branded products. In 2017, second trial in the FDA-sponsored EQUIGEN project confirmed that generic versions of lamotrigine appear bioequivalent to Lamictal, the brand-name form of the drug. Furthermore, Sunovion announced the submission of a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) for the use of Aptiom (eslicarbazepine acetate) as monotherapy or adjunctive therapy for the treatment of partial-onset seizures (POS) for children 4 years of age or below. Pfizer, Inc. has molecules NCT02072824, NCT01463306, and NCT01747915 in the pipeline indicated for epilepsy. Epygenix Therapeutics, Inc., in 2017, announced the U.S. FDA approval for orphan drug designation to EPX-100 and EPX-200 for treatment of patients with Dravet syndrome, which is a catastrophic form of epilepsy.
Browse 25 Market Data Tables and 35 Figures spread through 200 Pages and in-depth TOC on “Anti-Epileptic Drugs for Pediatrics Market by Drug Type (1st generation, 2nd generation, and 3rd generation), and Region (North America, Latin America, Europe, Asia-Pacific, the Middle East and Africa) – Global Forecast to 2025”
To know the latest trends and insights prevalent in the Anti-Epileptic Drugs for Pediatrics Market, click the link below: https://www.coherentmarketinsights.com/market-insight/anti-epileptic-drugs-for-pediatrics-market-823
Key Takeaways of the Anti-epileptic Drugs for Pediatrics Market:
- The global anti-epileptic drugs for pediatrics market is expected to exhibit a CAGR of 9% over the forecast period (2016–2025), owing to the presence of high potential markets, especially in Asia Pacific, Latin America, the Middle East, and Africa
- Robust developments in drug therapies, drugs showing potential in pipeline, and inclusion of generic versions of branded products in the market due to patent expiries are expected to drive the global anti-epileptic drugs for pediatrics market.
- Some major players operating in the anti-epileptic drugs for pediatrics market include Mylan N.V., Cephalon, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Novartis AG, Pfizer, Inc., Sanofi S.A., UCB Pharma Limited, Sunovion Pharmaceuticals Limited, Valeant Pharmaceuticals International, Inc., Zogenix, GW Pharmaceuticals, Insys, and Zynerba.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Media Contact
Company Name: Coherent Market Insights
Contact Person: Mr. Shah
Email: sales@coherentmarketinsights.com
Phone: +1-206-701-6702
Address:1001 4th Ave, #3200
City: Seattle
State: Washington
Country: United States
Website: https://www.coherentmarketinsights.com/market-insight/recombinant-vaccine-market-455